New Therapeutics in Alzheimer’s Disease longitudinal cohort study (NTAD): study protocol
<p><strong>Introduction</strong> With the pressing need to develop treatments that slow or stop the progression of Alzheimer’s disease, new tools are needed to reduce clinical trial duration and validate new targets for human therapeutics. Such tools could be derived from neurophys...
Main Authors: | Lanskey, JH, Kocagoncu, E, Quinn, AJ, Cheng, Y-J, Karadag, M, Pitt, J, Lowe, S, Perkinton, M, Raymont, V, Singh, KD, Woolrich, M, Nobre, AC, Henson, RN, Rowe, JB |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BMJ Publishing Group
2022
|
Similar Items
-
New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol
by: James B Rowe, et al.
Published: (2022-12-01) -
Reliability of dynamic causal modelling of resting‐state magnetoencephalography
by: Jafarian, A, et al.
Published: (2024) -
Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics
by: Kocagoncu, E, et al.
Published: (2020) -
Linking dopamine neurotransmission and neurogenesis: the evolutionary history of the NTAD (NCAM1-TTC12-ANKK1-DRD2) gene cluster
by: Nina Roth Mota, et al.
Published: (2012-01-01) -
Dissecting beta-state changes during timed movement preparation in Parkinson’s disease
by: Heideman, SG, et al.
Published: (2019)